{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T15:52:38Z","timestamp":1768837958508,"version":"3.49.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0011901","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000}}],"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["312802\/2020-0"],"award-info":[{"award-number":["312802\/2020-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["E-26\/201.176\/2021 (260734)"],"award-info":[{"award-number":["E-26\/201.176\/2021 (260734)"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006507","name":"Funda\u00e7\u00e3o Oswaldo Cruz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006507","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>The occurrence of adverse drug events (ADEs) during dapsone (DDS) treatment in patients with leprosy can constitute a significant barrier to the successful completion of the standardized therapeutic regimen for this disease. Well-known DDS-ADEs are hemolytic anemia, methemoglobinemia, hepatotoxicity, agranulocytosis, and hypersensitivity reactions. Identifying risk factors for ADEs before starting World Health Organization recommended standard multidrug therapy (WHO\/MDT) can guide therapeutic planning for the patient. The objective of this study was to develop a predictive model for DDS-ADEs in patients with leprosy receiving standard WHO\/MDT.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methodology<\/jats:title>\n<jats:p>This is a case-control study that involved the review of medical records of adult (\u226518 years) patients registered at a Leprosy Reference Center in Rio de Janeiro, Brazil. The cohort included individuals that received standard WHO\/MDT between January 2000 to December 2021. A prediction nomogram was developed by means of multivariable logistic regression (LR) using variables. The Hosmer\u2013Lemeshow test was used to determine the model fit. Odds ratios (ORs) and their respective 95% confidence intervals (CIs) were estimated. The predictive ability of the LRM was assessed by the area under the receiver operating characteristic curve (AUC).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 329 medical records were assessed, comprising 120 cases and 209 controls. Based on the final LRM analysis, female sex (OR = 3.61; 95% CI: 2.03\u20136.59), multibacillary classification (OR = 2.5; 95% CI: 1.39\u20134.66), and higher education level (completed primary education) (OR = 1.97; 95% CI: 1.14\u20133.47) were considered factors to predict ADEs that caused standard WHO\/MDT discontinuation. The prediction model developed had an AUC of 0.7208, that is 72% capable of predicting DDS-ADEs.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>We propose a clinical model that could become a helpful tool for physicians in predicting ADEs in DDS-treated leprosy patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pntd.0011901","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T18:46:50Z","timestamp":1706208410000},"page":"e0011901","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Development of a multivariate predictive model for dapsone adverse drug events in people with leprosy under standard WHO multidrug therapy"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5287-8697","authenticated-orcid":true,"given":"Ana Carolina Galv\u00e3o dos Santos","family":"de Araujo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana de Andrea Vilas-Boas","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta Olmo","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ximena","family":"Illarramendi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra Maria Barbosa","family":"Dur\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maur\u00edcio Lisboa","family":"Nobre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milton Oz\u00f3rio","family":"Moraes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Sales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilberto Marcelo Sperandio","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"issue":"4","key":"pntd.0011901.ref001","first-page":"525","article-title":"International open trial of uniform multidrug therapy regimen for leprosy patients: Findings & implications for national leprosy programmes","volume":"144","author":"P Manickam","year":"2016","journal-title":"Indian J Med Res"},{"key":"pntd.0011901.ref002","unstructured":"WHO. Guidelines for the Diagnosis, Treatment and Prevention of Leprosy. 2018; Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/274127\/9789290226383-eng.pdf."},{"key":"pntd.0011901.ref003","first-page":"1331","article-title":"The treatment of streptococcal infections in mice with 4:20 diaminodiphenylsulfone","volume":"229","author":"H Buttle G A","year":"1937"},{"issue":"3","key":"pntd.0011901.ref004","doi-asserted-by":"crossref","first-page":"221","DOI":"10.47276\/lr.83.3.221","article-title":"The chemotherapy of leprosy: an interpretive history","volume":"83","author":"RH Gelber","year":"2012","journal-title":"Lepr Rev"},{"issue":"1","key":"pntd.0011901.ref005","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0733-8635(05)70231-X","article-title":"DAPSONE AND SULFAPYRIDINE","volume":"19","author":"U Paniker","year":"2001","journal-title":"Dermatol Clin"},{"issue":"12","key":"pntd.0011901.ref006","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00210-022-02297-1","article-title":"A comprehensive insight into the anti-inflammatory properties of dapsone","volume":"395","author":"M Khalilzadeh","year":"2022","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"17","key":"pntd.0011901.ref007","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.3390\/ijms21175953","article-title":"4,4\u2032-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor","volume":"21","author":"J hoon Lee","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"17","key":"pntd.0011901.ref008","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","article-title":"HLA-B*13:01 and the dapsone hypersensitivity syndrome","volume":"369","author":"FR Zhang","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"pntd.0011901.ref009","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2340\/00015555-1268","article-title":"Hypersensitivity reactions to dapsone: a systematic review","volume":"92","author":"M Lorenz","year":"2012","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"pntd.0011901.ref010","article-title":"Increased incidence in leprosy of hypersensitivity reactions to dapsone after introduction of multidrug therapy","volume":"60","author":"JH Richardus","year":"1989","journal-title":"Lepr Rev"},{"issue":"2","key":"pntd.0011901.ref011","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.abd.2020.07.005","article-title":"Adverse effects of polychemotherapy for leprosy in 13 years of follow-up at a university hospital","volume":"96","author":"VD Tortelly","year":"2021","journal-title":"An Bras Dermatol"},{"issue":"12","key":"pntd.0011901.ref012","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/FPC.0000000000000306","article-title":"Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population","volume":"27","author":"T Tempark","year":"2017","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"pntd.0011901.ref013","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jid.2022.10.009","article-title":"TAP2 Drives HLA-B*13:01\u2013Linked Dapsone Hypersensitivity Syndrome Tolerance and Reactivity","volume":"143","author":"L Sun","year":"2023","journal-title":"J Invest Dermatol"},{"key":"pntd.0011901.ref014","doi-asserted-by":"crossref","first-page":"46","DOI":"10.47878\/hi.1995.v20.36487","article-title":"Intercorr\u00eancias pelas drogas utilizadas nos esquemas poliquimioter\u00e1picos em hansen\u00edase","author":"MEN Gallo","year":"1995","journal-title":"Hansen Int"},{"issue":"9","key":"pntd.0011901.ref015","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1345\/aph.1Q139","article-title":"Dapsone-Induced Methemoglobinemia: a Primer for Clinicians","volume":"45","author":"JA Barclay","year":"2011","journal-title":"Ann Pharmacother"},{"issue":"5","key":"pntd.0011901.ref016","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1590\/S0037-86822002000500005","article-title":"Efeitos adversos da poliquimioterapia em pacientes com hansen\u00edase: um levantamento de cinco anos em um Centro de Sa\u00fade da Universidade Federal de Uberl\u00e2ndia","volume":"35","author":"IMB Goulart","year":"2002","journal-title":"Rev Soc Bras Med Trop"},{"issue":"3","key":"pntd.0011901.ref017","doi-asserted-by":"crossref","first-page":"216","DOI":"10.47276\/lr.78.3.216","article-title":"Adverse effects from multi-drug therapy in leprosy: a Brazilian study","volume":"78","author":"PD Deps","year":"2007","journal-title":"Lepr Rev"},{"issue":"2","key":"pntd.0011901.ref018","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.det.2007.11.007","article-title":"Noncompliance with the World Health Organization-Multidrug Therapy Among Leprosy Patients in Cebu, Philippines: Its Causes and Implications on the Leprosy Control Program.","volume":"26","author":"ER Honrado","year":"2008","journal-title":"Dermatol Clin"},{"key":"pntd.0011901.ref019","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade [Internet]. Sect. 1, Nota t\u00e9cnica No 16\/2021-CGDE\/DCCI\/SVS\/MS Jun 25, 2021. Available from: https:\/\/www.conass.org.br\/wp-content\/uploads\/2021\/07\/SEI_MS-0020845770-Nota-Te%CC%81cnica-16.pdf."},{"issue":"1","key":"pntd.0011901.ref020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12879-019-4665-0","article-title":"World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis","volume":"20","author":"M Lazo-Porras","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"7","key":"pntd.0011901.ref021","doi-asserted-by":"crossref","first-page":"e488","DOI":"10.1371\/journal.pntd.0000488","article-title":"Feasibility, Drug Safety, and Effectiveness of Etiological Treatment Programs for Chagas Disease in Honduras, Guatemala, and Bolivia: 10-Year Experience of M\u00e9decins Sans Fronti\u00e8res","volume":"3","author":"O Yun","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"pntd.0011901.ref022","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"CA Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"pntd.0011901.ref023","doi-asserted-by":"crossref","first-page":"8","DOI":"10.47878\/hi.2014.v39.35024","article-title":"Efeitos adversos da poliquimioterapia para hansen\u00edase: utiliza\u00e7\u00e3o de doses alternativas e avalia\u00e7\u00e3o p\u00f3s alta","author":"RMM Kubota","year":"2014","journal-title":"Hansen Int"},{"issue":"4","key":"pntd.0011901.ref024","article-title":"Side-effects of antileprosy drugs in common use","volume":"54","author":"WH Jopling","year":"1983","journal-title":"Lepr Rev"},{"issue":"3","key":"pntd.0011901.ref025","doi-asserted-by":"crossref","first-page":"209","DOI":"10.47276\/lr.84.3.209","article-title":"Intolerance to leprosy multi-drug therapy: more common in women?","volume":"84","author":"KM Dupnik","year":"2013","journal-title":"Lepr Rev"},{"issue":"1","key":"pntd.0011901.ref026","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"I Zucker","year":"2020","journal-title":"Biol Sex Differ"},{"issue":"1","key":"pntd.0011901.ref027","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1038\/s41467-022-35266-6","article-title":"Sex differences in allometry for phenotypic traits in mice indicate that females are not scaled males","volume":"13","author":"LAB Wilson","year":"2022","journal-title":"Nat Commun"},{"key":"pntd.0011901.ref028","article-title":"Factors associated with underreporting of adverse drug reactions by patients: a systematic review","author":"C Costa","year":"2023","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"pntd.0011901.ref029","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00003088-198916060-00003","article-title":"Clinical Pharmacokinetic Considerations in the Treatment of Patients with Leprosy","volume":"16","author":"K. Venkatesan","year":"1989","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"pntd.0011901.ref030","first-page":"400","article-title":"Influence of acetylator phenotype of the leprosy patient on the emergence of dapsone resistant leprosy","volume":"60","author":"PP Raj","year":"1988","journal-title":"Indian J Lepr"},{"key":"pntd.0011901.ref031","doi-asserted-by":"crossref","first-page":"113993","DOI":"10.1016\/j.bcp.2020.113993","article-title":"Metabolism and interactions of antileprosy drugs","volume":"177","author":"J George","year":"2020","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"pntd.0011901.ref032","doi-asserted-by":"crossref","first-page":"e0189322","DOI":"10.1371\/journal.pone.0189322","article-title":"Time to development of adverse drug reactions and associated factors among adult HIV positive patients on antiretroviral treatment in Bahir Dar City, Northwest Ethiopia","volume":"12","author":"E Kindie","year":"2017","journal-title":"PLOS ONE"},{"issue":"1","key":"pntd.0011901.ref033","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1186\/s12885-022-09599-w","article-title":"The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-TKI therapy","volume":"22","author":"R Du","year":"2022","journal-title":"BMC Cancer"},{"issue":"3","key":"pntd.0011901.ref034","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.alit.2019.03.006","article-title":"Drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019","volume":"68","author":"T Shiohara","year":"2019","journal-title":"Allergol Int"},{"issue":"35","key":"pntd.0011901.ref035","doi-asserted-by":"crossref","first-page":"7908","DOI":"10.3748\/wjg.v22.i35.7908","article-title":"Anemia and iron deficiency in gastrointestinal and liver conditions","volume":"22","author":"J Stein","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"10","key":"pntd.0011901.ref036","doi-asserted-by":"crossref","first-page":"e0008746","DOI":"10.1371\/journal.pntd.0008746","article-title":"Validation study of HLA-B*13:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia","volume":"14","author":"H Krismawati","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0011901.ref037","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2146\/ajhp160961","article-title":"Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency","volume":"75","author":"KD Belfield","year":"2018","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"pntd.0011901.ref038","doi-asserted-by":"crossref","first-page":"232","DOI":"10.47276\/lr.91.3.232","article-title":"The adverse drug effects of dapsone: a systematic review","volume":"91","author":"R Hilder","year":"2020","journal-title":"Lepr Rev"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0011901","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T18:44:07Z","timestamp":1707245047000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011901"}},"subtitle":[],"editor":[{"given":"Alberto Novaes","family":"Ramos","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0011901","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0011901","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]}}}